Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate
Warin R, Xiao D, Arlotti JA, Bommareddy A, Singh SV
Molecular carcinogenesis · 56 citas
Cómo se estudió
- Diseño
- Estudio en animales (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas, más trabajo en animales o laboratorio
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Cancer Institute
- Gobierno
- NCI NIH HHS
- Subvenciones
- National Cancer Institute (R01 CA129347); National Cancer Institute (CA129347)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2010-04-21 · Mol Carcinog · vol. 49 · número 5 · págs. 500–507
- Editorial
- Wiley
- Citado
- 77 citas · más que el 90% de estudios similares · 2.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 36 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Fungal Plant Pathogen Control · Glutathione Transferases and Polymorphisms
- Palabras clave
- Benzyl isothiocyanate, Angiogenesis, In vivo, Biology, Cancer research, Vascular endothelial growth factor, Cell growth, Terminal deoxynucleotidyl transferase, Neovascularization, Cancer, CD31, Apoptosis, Pharmacology, Endocrinology, TUNEL assay, Isothiocyanate, Biochemistry, VEGF receptors
- MeSH
- cell line, tumor, animals, humans, mice, mice, nude, vegetables, breast neoplasms, isothiocyanates, transplantation, heterologous, immunohistochemistry, in situ nick-end labeling, female
5 autores
- Renaud Warin🇺🇸University of Pittsburgh; UPMC Hillman Cancer Center
- Dong Xiao🇺🇸UPMC Hillman Cancer Center
- Julie A. Arlotti🇺🇸UPMC Hillman Cancer Center
- Ajay Bommareddy🇺🇸UPMC Hillman Cancer Center
- Shivendra Vikram Singh🇺🇸 · autor de correspondenciaUPMC Hillman Cancer Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Benzyl isothiocyanate (BITC), a constituent of cruciferous vegetables such as garden cress, inhibits growth of human breast cancer cell lines in culture. The present study was undertaken to determine in vivo efficacy of BITC against MDA-MB-231 human breast cancer xenografts. The BITC administration retarded growth of MDA-MB-231 cells subcutaneously implanted in female nude mice without causing weight loss or any other side effects. The BITC-mediated suppression of MDA-MB-231 xenograft growth correlated with reduced cell proliferation as revealed by immunohistochemical analysis for Ki-67 expression. Analysis of the vasculature in the tumors from BITC-treated mice indicated smaller vessel area compared with control tumors based on immunohistochemistry for angiogenesis marker CD31. The BITC-mediated inhibition of angiogenesis in vivo correlated with downregulation of vascular endothelial growth factor (VEGF) receptor 2 protein levels in the tumor. Consistent with these results, BITC treatment suppressed VEGF secretion and VEGF receptor 2 protein levels in cultured MDA-MB-231 cells. Moreover, the BITC-treated MDA-MB-231 cells exhibited reduced capacity for migration compared with vehicle-treated control cells. In contrast to cellular data, BITC administration failed to elicit apoptotic response as judged by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. In conclusion, the present study demonstrates in vivo anti-cancer efficacy of BITC against MDA-MB-231 xenografts in association with reduced cell proliferation and suppression of neovascularization. These preclinical observations merit clinical investigation to determine efficacy of BITC against human breast cancers.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.